Canaccord initiated coverage of Marker Therapeutics (MRKR) with a Buy rating and $8 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRKR:
Questions or Comments about the article? Write to editor@tipranks.com